Elite Pharmaceuticals to Receive up to 40 Million from Lincoln Park Capital Fund
ACCESS Newswire
April 15, 2014
Elite Pharmaceuticals Inc. (OTCBB:ELTP - News) announced Apr. 14 that it has entered into a common stock purchase agreement with Lincoln Park Capital Fund LLC ("LPC"), a Chicago-based institutional investor for up to $40 million.
Proceeds from the transaction will be used to develop the company's pipeline of products, including the abuse resistant opioids, and for general corporate purposes.